JAZZ (Jazz Pharmaceuticals) Total Liabilities : $8,085 Mil (As of Sep. 2024)

View and export this data going back to 2007. Start your Free Trial

What is Jazz Pharmaceuticals Total Liabilities?

Jazz Pharmaceuticals's Total Liabilities for the quarter that ended in Sep. 2024 was $8,085 Mil.

Jazz Pharmaceuticals's quarterly Total Liabilities declined from Mar. 2024 ($7,630.61 Mil) to Jun. 2024 ($7,599.27 Mil) but then increased from Jun. 2024 ($7,599.27 Mil) to Sep. 2024 ($8,084.65 Mil).

Jazz Pharmaceuticals's annual Total Liabilities declined from Dec. 2021 ($8,333.45 Mil) to Dec. 2022 ($7,749.52 Mil) and declined from Dec. 2022 ($7,749.52 Mil) to Dec. 2023 ($7,656.36 Mil).

Jazz Pharmaceuticals Total Liabilities Historical Data

The historical data trend for Jazz Pharmaceuticals's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Jazz Pharmaceuticals Total Liabilities Chart

Jazz Pharmaceuticals Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Liabilities

Get a 7-Day Free Trial

2,427.92

2,876.16

8,333.45

7,749.52

7,656.36

Jazz Pharmaceuticals Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Total Liabilities	Get a 7-Day Free Trial															7,714.69	7,656.36	7,630.61	7,599.27	8,084.65

Jazz Pharmaceuticals Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Jazz Pharmaceuticals's Total Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	1536.692	+	(5167.213	+	104.751
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	847.706	+	0)
	=	7,656

Total Liabilities	=	Total Assets (A: Dec. 2023 )	-	Total Equity (A: Dec. 2023 )
	=	11393.359	-	3736.997
	=	7,656

Jazz Pharmaceuticals's Total Liabilities for the quarter that ended in Sep. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	1029.977	+	(6151.917	+	110.971
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	791.784	+	0)
	=	8,085

Total Liabilities	=	Total Assets (Q: Sep. 2024 )	-	Total Equity (Q: Sep. 2024 )
	=	12255.716	-	4171.067
	=	8,085

Jazz Pharmaceuticals Total Liabilities Related Terms

Thank you for viewing the detailed overview of Jazz Pharmaceuticals's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Jazz Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Jazz Pharmaceuticals PLC (NAS:JAZZ) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

J7Z:Germany J7Z:Germany

Address

Waterloo Road, Fifth Floor, Waterloo Exchange, Dublin, IRL, D04 E5W7

Website

https://www.jazzpharmaceuticals.com

Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.

Executives

Bruce C Cozadd	director, officer: Executive Chairman	C/O JAZZ PHARMACEUTICALS PLC, 5TH FL, WATERLOO EXCHANGE, WATERLOO RD, DUBLIN L2 4 L2 00000
Patricia Carr	officer: VP, Finance& PAO	JAZZ PHARMACEUTICALS, 3170 PORTER DRIVE, PALO ALTO CA 94304
Neena M Patil	officer: SVP, General Counsel	JAZZ PHARMACEUTICALS, 3170 PORTER DRIVE, PALO ALTO CA 94304
Mary Elizabeth Henderson	officer: SVP, Technical Operations	3170 PORTER DRIVE, PALO ALTO CA 94304
Jennifer E. Cook	director	C/O DENALI THERAPEUTICS INC., 151 OYSTER POINT BLVD., 2ND FLOOR, SOUTH SAN FRANCISCO CA 94080
Mark Douglas Smith	director	C/O TELADOC HEALTH, INC., 2 MANHATTANVILLE ROAD, SUITE 203, PURCHASE NY 10577
Patrick G Enright	director, 10 percent owner	CO LONGITUDE CAPITAL PARTNERS LLC, 800 EL CAMINO REAL, SUITE 220, MENLO PARK CA 94025
Norbert G Riedel	director	BAXTER INTERNATIONAL INC, ONE BAXTER PKWY DF2-1W, DEERFIELD IL 60015
Catherine A. Sohn	director	C/O JAZZ PHARMACEUTICALS PLC, 5TH FL, WATERLOO EXCHANGE, WATERLOO RD, DUBLIN L2 4 L2
Rick E Winningham	director	901 GATEWAY BOULEVARD, SOUTH SAN FRANCISCO CA 94080
Heather Ann Mcsharry	director	C/O JAZZ PHARMACEUTICALS PLC, 5TH FL, WATERLOO EXCHANGE, WATERLOO RD, DUBLIN L2 4 L2
Peter Gray	director	C/O JAZZ PHARMACEUTICALS PLC, 5TH FL, WATERLOO EXCHANGE, WATERLOO RD, DUBLIN L2 4 L2
Anne Oriordan	director	HOUSE 120, TAI HANG HAU VILLAGE, LOBSTER BAY, CLEARWATER BAY K3 HK
Kenneth W O'keefe	director	C/O BEECKEN PETTY O'KEEFE & COMPANY, 131 S. DEARBORN STREET, SUITE 2800, CHICAGO IL 60603
Renee D Gala	officer: EVP & CFO	901 GATEWAY BLVD, SOUTH SAN FRANCISCO CA 94080